Meeting
2021 ASCO Annual Meeting
Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.
Authors
Jermaine Coward
ICON Cancer Care, South Brisbane, QLD, Australia
Jermaine Coward , Anna Rachelle Austria Mislang , Sophia Frentzas , Charlotte Rose Lemech , Adnan Nagrial , Xiaoping Jin , Baiyong Li , Zhongmin Maxwell Wang , Kon Yew Kwek , Yu Xia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT04047290
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2515)
DOI
10.1200/JCO.2021.39.15_suppl.2515
Abstract #
2515
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Safety and efficacy of HB0025, an anti-PD-1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: Preliminary results from an FIH trial.
First Author: Yiqun Du
Poster
2021 ASCO Annual Meeting
A phase I study of an IDO inhibitor (SHR9146) plus camrelizumab and in combination with/without apatinib in patients with advanced solid tumors: Safety and efficacy analysis.
First Author: Ying Cheng
Poster
2019 ASCO Annual Meeting
A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy.
First Author: Timothy A Yap
Poster
2018 ASCO Annual Meeting
Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).
First Author: Andreea Varga